Fujifilm Kyowa Kirin JV lines up bevacizumab as next biosimilar target
This article was originally published in Scrip
Executive Summary
Fujifilm Kyowa Kirin Biologics, the equally owned joint venture between Japan's Fujifilm and Kyowa Hakko Kirin, has unveiled Roche/Genentech's big-selling anticancer antibody Avastin (bevacizumab) as the next project in its growing pipeline of biosimilars.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.